Deck 7

DECK7.IO

Deck 7 is a digital marketing and media company that works with brands, agencies, and platforms worldwide on brand awareness and lead generation programs. Who we are – Deck 7 is a digital marketing and media company that provides brand awareness and lead generation services worldwide. The Deck 7 team consists of over 300 marketing specialists, data science experts, and martech engineers that execute and orchestrate over 2,800 campaigns each year. What we do – Deck 7 provides performance-based marketing services by orchestrating multi-channel campaigns across email, web, mobile, voice, social, search, and display. Media 7 is a network of media properties across 16 industries that provide marketers with multiple options to target markets, reach audiences, and develop accounts across 120 countries.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INTENT DATA IN THE AGE OF DATA REGULATION

DECK 7 | March 23, 2020

news image

Since the implementation of Data Protection Act in 2018, the approach behind the use of data has changed dramatically. Our clients and customers don’t just want a great experience, they also want to make sure they can trust us. Tweet This! And it makes perfect sense in the present time and space. But as data is considered a key factor in positive customer experience, the U.S. brands and agencies have found it to be increasingly complicated to earn customer trust while rem...

Read More

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

news image

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More

J&J JUMPING IN ON CORONAVIRUS VAX WORK AS DISEASE CONTINUES ITS SPREAD

FierceBiotech | January 27, 2020

news image

Johnson & Johnson is joining the growing ranks of biopharmas, including the likes of Moderna and Gilead Sciences, in trying to create a speedy vaccine for the coronavirus out of China. Over the weekend, we learned of a wider range and more deaths as the new virus, which appears to have come out of Wuhan, China, is doing what these diseases do best: spread. The causes of death have so far been reported as pneumonia, with other reports suggesting most of these have come from those with underly...

Read More

LABCORP'S CRO UNIT COVANCE DOUBLES DOWN ON CELL, GENE THERAPY OFFERINGS

FierceBiotech | January 21, 2020

news image

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get in on this burgeoning new trend. “These solutions are designed to reduce time and risk for sponsors at each phase and across the full continuum of their therapy development needs in one of the industry’s fastest-growing segments,” Covance, the CRO unit of diagnostics giant LabCorp, said in a statement. This follows the first CAR-T cell therapy approvals from Novartis ...

Read More
news image

INTENT DATA IN THE AGE OF DATA REGULATION

DECK 7 | March 23, 2020

Since the implementation of Data Protection Act in 2018, the approach behind the use of data has changed dramatically. Our clients and customers don’t just want a great experience, they also want to make sure they can trust us. Tweet This! And it makes perfect sense in the present time and space. But as data is considered a key factor in positive customer experience, the U.S. brands and agencies have found it to be increasingly complicated to earn customer trust while rem...

Read More
news image

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More
news image

J&J JUMPING IN ON CORONAVIRUS VAX WORK AS DISEASE CONTINUES ITS SPREAD

FierceBiotech | January 27, 2020

Johnson & Johnson is joining the growing ranks of biopharmas, including the likes of Moderna and Gilead Sciences, in trying to create a speedy vaccine for the coronavirus out of China. Over the weekend, we learned of a wider range and more deaths as the new virus, which appears to have come out of Wuhan, China, is doing what these diseases do best: spread. The causes of death have so far been reported as pneumonia, with other reports suggesting most of these have come from those with underly...

Read More
news image

LABCORP'S CRO UNIT COVANCE DOUBLES DOWN ON CELL, GENE THERAPY OFFERINGS

FierceBiotech | January 21, 2020

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get in on this burgeoning new trend. “These solutions are designed to reduce time and risk for sponsors at each phase and across the full continuum of their therapy development needs in one of the industry’s fastest-growing segments,” Covance, the CRO unit of diagnostics giant LabCorp, said in a statement. This follows the first CAR-T cell therapy approvals from Novartis ...

Read More